This new product is bioequivalent and therapeutically equivalent to the reference-listed drug, Evoclin Foam, 1%, manufactured ...

Glenmark Pharmaceuticals's US arm has launched a generic version of Clindamycin Phosphate foam, an antibiotic acne treatment.

Glenmark Pharmaceuticals has announced the launch of Clindamycin Phosphate Foam, which is a bioequivalent and therapeutically equivalent to the reference listed drug, Evoclin Foam of Mylan ...

Glenmark Pharmaceuticals and Cosmo Pharmaceuticals have received MHRA approval to market Winlevi, a topical acne treatment ...

Glenmark Pharmaceuticals Ltd, in collaboration with Cosmo Pharmaceuticals N.V., has received approval from the UK Medicines ...

Glenmark Pharmaceuticals Ltd's US division has introduced a generic version of Clindamycin Phosphate foam, an acne treatment. This product is equivalent to Mylan's Evoclin foam and joins a market with ...

Glenmark Pharmaceuticals Ltd on Wednesday said its US arm has launched the generic version of Clindamycin Phosphate foam, an.

Glenmark Pharmaceuticals and Ireland-based Cosmo Pharmaceuticals NV have received approval from the Medicines and Healthcare ...

Inc., USA, has announced the launch of Clindamycin Phosphate Foam, 1%, a product that is bioequivalent and therapeutically ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of clindamycin phosphate foam, 1%. Glenmark’s clindamycin phosphate foam, 1% is bioequivalent and therapeutically equivalent to the ...

Dublin, Ireland and Mumbai, India and London, United Kingdom--( - February 10, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) and Glenmark Pharmaceuticals Limited (Glenmark), a ...

Glenmark Pharmaceuticals receives UK approval for Winlevi, a groundbreaking topical acne treatment with unique mechanism of ...